BridgeBio Pharma Inc to Discuss Proof-of-Concept Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 Transcript
Good morning, ladies Ladies and gentlemen, and welcome to BridgeBio Pharma's call to discuss proof-of-concept data for encaleret and ADH1. (Operator Instructions). As a reminder, today's conference call is being recorded.
I'd now like to turn the conference over to your host, Dr. Neil Kumar, Founder and CEO of BridgeBio Pharma. Please go ahead.
Thank you, operator, and thanks, everyone, for joining today's call. Before I dive in, I have to do the customary forward-looking statement here. So before we begin, I'll remind everyone that this presentation is being webcast and includes forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. You all know the rest.
So let's dive in. The purpose of today's call, which I hope is clear, is to discuss the positive and extremely encouraging data that were released this weekend at ENDO, detailing the latest in our efforts that many of you know about to treat autosomal
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
